The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects

Diabetologia. 2017 Mar;60(3):395-398. doi: 10.1007/s00125-016-4194-y. Epub 2017 Jan 11.

Authors

Roberto Vettor¹, Silvio E Inzucchi², Paola Fioretto³

Affiliations

¹ Internal Medicine 3, Department of Medicine, University of Padua, via Giustiniani 2, 35128, Padova, Italy. roberto.vettor@unipd.it.
² Section of Endocrinology, Yale University School of Medicine, New Haven, CT, USA.
³ Internal Medicine 3, Department of Medicine, University of Padua, via Giustiniani 2, 35128, Padova, Italy. paola.fioretto@unipd.it.

PMID: 28074254
DOI: 10.1007/s00125-016-4194-y

No abstract available

Keywords: Cardiovascular disease; Empagliflozin; Heart failure; Mitochondrial function; NHE; SGLT2 inhibitors; Type 2 diabetes.

Publication types

Editorial

MeSH terms

Benzhydryl Compounds / adverse effects
Benzhydryl Compounds / therapeutic use*
Cardiovascular Diseases / complications
Cardiovascular Diseases / metabolism
Cardiovascular Diseases / prevention & control*
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy*
Diabetic Angiopathies / prevention & control
Diabetic Cardiomyopathies / prevention & control
Glucosides / adverse effects
Glucosides / therapeutic use*
Humans
Hypoglycemic Agents / adverse effects
Hypoglycemic Agents / therapeutic use*
Membrane Transport Modulators / adverse effects
Membrane Transport Modulators / therapeutic use*
Models, Biological*
Sodium-Glucose Transporter 2 / metabolism
Sodium-Glucose Transporter 2 Inhibitors*

Substances

Benzhydryl Compounds
Glucosides
Hypoglycemic Agents
Membrane Transport Modulators
SLC5A2 protein, human
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors
empagliflozin